Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease — Stella

Home/Sjogren's Syndrome/

View on ClinicalTrials.gov

Recruiting

Back to Sjogren's Syndrome trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

National Institutes of Health Clinical Center, Bethesda, Maryland

Key details

Phase

Safety & dosing

Sponsor

National Institute of Dental and Craniofacial Research (NIDCR)

Enrollment target

~60 participants

Started

December 2025

Primary completion

December 2030

Age range

18 Years – 75 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.